tiprankstipranks
Trending News
More News >
MAIA Biotechnology, Inc. (MAIA)
:MAIA
US Market

MAIA Biotechnology, Inc. (MAIA) AI Stock Analysis

Compare
220 Followers

Top Page

MA

MAIA Biotechnology, Inc.

(NYSE MKT:MAIA)

Rating:44Neutral
Price Target:
MAIA Biotechnology presents a mixed outlook. The company's financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

MAIA Biotechnology, Inc. (MAIA) vs. SPDR S&P 500 ETF (SPY)

MAIA Biotechnology, Inc. Business Overview & Revenue Model

Company DescriptionMAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
How the Company Makes MoneyMAIA Biotechnology, Inc. makes money primarily through the development and commercialization of oncology therapies. The company's revenue model includes securing funding through partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These partnerships often involve milestone payments, royalties, and upfront fees linked to the development and eventual commercialization of their drug candidates. Additionally, MAIA may also receive government grants or research funding to support its clinical trials and research activities. As the company progresses its drug candidates through clinical trials and towards regulatory approval, it aims to generate revenue through the successful commercialization of these therapies.

MAIA Biotechnology, Inc. Financial Statement Overview

Summary
MAIA Biotechnology, Inc. is in a development phase with no revenue and significant ongoing expenses leading to negative profitability and cash flows. The balance sheet is strengthened by zero debt, but equity is limited. The financial outlook depends heavily on successful future product development and potential funding opportunities.
Income Statement
15
Very Negative
MAIA Biotechnology, Inc. shows no revenue generation, typical for early-stage biotech firms focusing on R&D. The company has consistently reported negative EBIT and net income, reflecting the high costs associated with drug development without corresponding revenue. This creates a challenging profitability outlook in the short term.
Balance Sheet
25
Negative
The balance sheet highlights a low debt profile with no outstanding debt, which is positive. However, the stockholders' equity is relatively small, limiting financial flexibility. The company's equity ratio is marginal and has fluctuated over the years, indicating potential volatility in financial stability.
Cash Flow
20
Very Negative
Operating cash flow has been consistently negative due to ongoing operational expenses without revenue. Free cash flow remains deeply negative, though financing activities have helped maintain liquidity. The cash flow situation reflects a need for external funding to support operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
EBITDA-20.63M-16.96M-20.18M-16.18M-7.74M-6.97M
Net Income-19.70M-23.25M-19.77M-15.81M-12.50M-6.64M
Balance Sheet
Total Assets11.86M10.16M7.57M12.02M11.33M746.50K
Cash, Cash Equivalents and Short-Term Investments10.86M9.60M7.15M10.95M10.57M663.46K
Total Debt0.000.000.000.000.00463.75K
Total Liabilities6.92M6.52M7.09M3.51M2.15M2.36M
Stockholders Equity4.94M3.63M477.51K8.51M9.18M-3.34M
Cash Flow
Free Cash Flow-16.32M-15.70M-13.07M-11.66M-4.12M-1.84M
Operating Cash Flow-16.32M-15.70M-13.07M-11.66M-4.12M-1.84M
Investing Cash Flow0.000.000.000.000.000.00
Financing Cash Flow18.92M18.18M9.27M12.48M14.03M798.05K

MAIA Biotechnology, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.90
Price Trends
50DMA
1.87
Positive
100DMA
1.77
Positive
200DMA
2.07
Negative
Market Momentum
MACD
<0.01
Negative
RSI
56.86
Neutral
STOCH
67.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MAIA, the sentiment is Positive. The current price of 1.9 is above the 20-day moving average (MA) of 1.78, above the 50-day MA of 1.87, and below the 200-day MA of 2.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.86 is Neutral, neither overbought nor oversold. The STOCH value of 67.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MAIA.

MAIA Biotechnology, Inc. Risk Analysis

MAIA Biotechnology, Inc. disclosed 72 risk factors in its most recent earnings report. MAIA Biotechnology, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

MAIA Biotechnology, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
51
Neutral
$53.65M-59.49%21.15%46.44%
50
Neutral
$58.05M-119.22%25.51%
46
Neutral
$50.61M-290.21%-100.00%44.28%
44
Neutral
$56.07M-1131.02%23.55%
41
Neutral
$48.12M2.40-50.81%-11.11%79.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MAIA
MAIA Biotechnology, Inc.
1.85
-1.48
-44.44%
PDSB
PDS Biotechnology
1.33
-1.79
-57.37%
DTIL
Precision BioSciences
4.34
-4.86
-52.83%
KRON
Kronos Bio
0.88
-0.27
-23.48%
GANX
Gain Therapeutics
1.69
0.49
40.83%

MAIA Biotechnology, Inc. Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025
Positive
Mar 28, 2025

MAIA Biotechnology, Inc. presented a poster at the European Lung Cancer Congress 2025 on March 28, 2025, showcasing efficacy data from its Phase 2 THIO-101 clinical trial. The trial evaluates THIO in combination with the immune checkpoint inhibitor cemiplimab for patients with advanced non-small cell lung cancer who have not responded to standard therapies. This presentation highlights the company’s ongoing efforts to advance its clinical research and potentially improve treatment options for lung cancer patients.

Executive/Board ChangesBusiness Operations and Strategy
MAIA Biotechnology Updates Executive Compensation Packages
Neutral
Feb 6, 2025

On February 1, 2025, MAIA Biotechnology, Inc. announced updates to the employment agreements of key executives, including Dr. Vlad Vitoc, Chairman and CEO, and Dr. Sergei Gryaznov, Chief Scientific Officer. These amendments included salary increases and revised bonus structures, enhancing their compensation packages based on performance objectives and corporate goals. The changes reflect a strategic move to retain top leadership talent and align executive incentives with company goals, potentially impacting the company’s operational strategy and competitive positioning in the biotech industry.

Product-Related AnnouncementsBusiness Operations and Strategy
MAIA Biotechnology Reports Promising Phase 2 Trial Results
Positive
Feb 5, 2025

On February 4, 2025, MAIA Biotechnology announced positive updates from its Phase 2 THIO-101 trial for advanced non-small cell lung cancer. The trial showed a significant median overall survival of 16.9 months, suggesting a strong advantage over standard chemotherapy treatments. This development enhances MAIA’s regulatory strategy and could expedite FDA approval, marking a potential breakthrough for patients with limited treatment options.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025